Cabaletta Bio provides updated clinical milestones: RESET data at ACR 2024, MG data H1 2025

Cabaletta Bio, Inc.

Additional clinical data from RESET-SLE and RESET-Myositis trials to be presented at ACR Convergence 2024 in November.
Initial clinical data from the RESET-SSc trial also scheduled for ACR Convergence 2024.
Initial clinical data from the RESET-MG trial anticipated in the first half of 2025.
Updated corporate presentation posted on the company website with these milestones.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.